

October 12, 2026

National Stock Exchange of India Limited
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex, Bandra (E)
Mumbai – 400 051

BSE Limited
Corporate Relationship Department
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai – 400 001

Symbol: LALPATHLAB

Scrip Code: 539524

Sub: Update on further investment in PathLabs Unifiers Private Limited, a Wholly Owned Subsidiary

Dear Sir/ Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“the Listing Regulations”), we wish to inform you that Dr. Lal PathLabs Limited (“the Company”) has made a further investment in PathLabs Unifiers Private Limited (“PUPL”), a Wholly Owned Subsidiary of the Company, by subscribing to the equity shares of PUPL on October 12, 2026.

The disclosure(s) as required under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023, as amended from time to time, is enclosed herewith as “**Annexure – A**”.

We request you to please take the same on record.

Thanking You,

Yours Faithfully,

For **Dr. Lal PathLabs Limited**

Vinay
Gujral

Digitally signed
by Vinay Gujral
Date: 2026.10.12
13:57:53 +05'30'

Vinay Gujral
Company Secretary & Compliance Officer
Encl: as above

Annexure-A
DISCLOSURE AS PER REGULATION 30 OF LISTING REGULATIONS READ WITH SEBI CIRCULAR NO. SEBI/HO/CFD/CFD-POD-1/P/CIR/2023/123 DATED JULY 13, 2023:

SN	Particulars	Acquisition of Company
1	Name of the target entity, details in brief such as size, turnover etc.	PathLabs Unifiers Private Limited ("PUPL") Turnover: FY 2026: 7.23 Crores FY 2025: 7.10 Crores FY 2024: 7.28 Crores
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arm's length"	PUPL, being a Wholly Owned Subsidiary is a related party of the Company. The proposed investment is in the nature of related party transaction and will be on an arm's length basis.
3	Industry to which the entity being acquired belongs	Healthcare/ Diagnostics Services
4	Objects and impact of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	The proposed subscription of shares is intended to fund the acquisition by PUPL, remaining 30% equity stake in CentraPath Labs Private Limited ("CPL"), Subsidiary of PUPL. Post this acquisition, CPL will become Wholly Owned Subsidiary of PUPL.
5	Brief details of any governmental or regulatory approvals required for the acquisition	Not Applicable
6	Indicative time period for completion of the acquisition	Completed
7	Consideration - whether cash consideration or share swap or any other form and details of the same	Cash Consideration
8	Cost of acquisition and/or the price at which the shares are acquired	Not exceeding INR 30.3 Crores.
9	Percentage of shareholding / control acquired and / or number of shares acquired	PUPL shall continue to remain a Wholly Owned Subsidiary of the Company.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	PUPL was incorporated on December 12, 2018, in National Capital Territory Delhi and is engaged in business of providing Healthcare/ Diagnostics Services. Turnover: As mentioned in Clause 1 above